Both imPERCIST5 and PERCIMT are immune-modified response criteria that were initially studied in cohorts of melanoma patients treated with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) agent Ipilimumab. This evidence concerns the gene CTLA4 and melanoma.